Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT

Clinical trial NCT00648037 · COMPLETED

Trial details

NCT number: NCT00648037
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

Hodgkin's Disease Leukemia Myelodysplastic Syndrome Non-Hodgkin's Lymphoma

Start date: 2008-03-01
Primary completion: 2008-12-01
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.